Bifidobacterium longum infantis

DB14222ApprovedInvestigationalWithdrawnOrganism Based Therapies

Bifidobacterium longum infantis is a probiotic indicated in the treatment of infectious and non-specific diarrhea. A good bacteria used to treat diarrhea.

Also known as
Bifidobacterium infantis · Bifidobacterium infantis whole · Bifidobacterium lactentis whole · Bifidobacterium liberorum whole · Bifidobacterium longum bv. infantis whole

Resolves to

Compound
UNIIEF3U3H7I76
Clinical / RWD
RxNorm100213

What you can answer from here — as of July 24, 2025

17Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
5ContraindicationsEach with its own population and attribute set
Sign in
2Marketed productsAcross 2 countries and 2 labellers
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Bifidobacterium longum infantis, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In